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Abstract
Objective
To evaluate the safety and eﬃcacy of L-serine in humans with hereditary sensory autonomic
neuropathy type I (HSAN1).
Methods
In this randomized, placebo-controlled, parallel-group trial with open-label extension, patients
aged 18–70 years with symptomatic HSAN1 were randomized to L-serine (400 mg/kg/day) or
placebo for 1 year. All participants received L-serine during the second year. The primary
outcome measure was the Charcot-Marie-Tooth Neuropathy Score version 2 (CMTNS).
Secondary outcomes included plasma sphingolipid levels, epidermal nerve ﬁber density, elec-
trophysiologic measurements, patient-reported measures, and adverse events.
Results
Between August 2013 and April 2014, we enrolled and randomized 18 participants, 16 of whom
completed the study. After 1 year, the L-serine group experienced improvement in CMTNS
relative to the placebo group (−1.5 units, 95% CI −2.8 to −0.1, p = 0.03), with evidence of
continued improvement in the second year of treatment (−0.77, 95% CI −1.67 to 0.13, p =
0.09). Concomitantly, deoxysphinganine levels dropped in L-serine-treated but not placebo-
treated participants (59% decrease vs 11% increase; p < 0.001). There were no serious adverse
eﬀects related to L-serine.
Conclusion
High-dose oral L-serine supplementation appears safe in patients with HSAN1 and is poten-
tially eﬀective at slowing disease progression.
Clinicaltrials.gov identifier
NCT01733407.
Classification of evidence
This study provides Class I evidence that high-dose oral L-serine supplementation signiﬁcantly
slows disease progression in patients with HSAN1.
MORE ONLINE
Class of Evidence
Criteria for rating
therapeutic and diagnostic
studies
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Hereditary sensory autonomic neuropathy type I (HSAN1) is
a debilitating, progressive disorder of peripheral nerve that
results in sensory loss, neuropathic pain, varying degrees of
limb weakness, and mutilating skin ulceration severe enough
to cause infection and warrant limb amputation.1 The disease
most commonly results frommissense mutations in the genes
SPTLC1 and SPTLC2, which encode for 2 of the 3 subunits of
serine palmitoyltransferase (SPT). SPT catalyzes the ﬁrst step
in the de novo synthesis of sphingolipids by conjugating
palmitoyl-CoA and L-serine.2,3 HSAN1 mutations reduce
the aﬃnity of the enzyme for L-serine and increase its aﬃnity
for alanine and glycine, thereby leading to formation of an
atypical class of neurotoxic 1-deoxysphingolipids (1-deoxySLs).4,5
To date, no eﬀective disease-modifying therapy has been
identiﬁed for HSAN1 or for any of the varied forms of
Charcot-Marie-Tooth (CMT) disease.
The discovery that HSAN1 is driven by the formation of toxic
lipid metabolites has provided a unique opportunity to devise
a biologically rational and potentially disease-modifying
therapy. Two important ﬁndings have implicated 1-deoxySL
in HSAN1 pathogenesis. First, 1-deoxySLs accumulate pref-
erentially in the peripheral nerves of transgenic HSAN1 mice
while sparing the CNS. Second, 1-deoxySLs are neurotoxic
and aﬀect neurite outgrowth in cultures of dorsal root
ganglia.4–6 Elevated 1-deoxySLs have also been demonstrated
in type 2 diabetes mellitus, where they might contribute to
beta cell failure, and in diabetic neuropathy, which shares
many phenotypic features with HSAN1.7–9
Importantly, it has been demonstrated that 1-deoxySL for-
mation in humans and mice can be reduced with high doses of
L-serine, the normal substrate of SPT.10 Dietary supplemen-
tation in transgenic mice resulted in signiﬁcant reductions of
plasma 1-deoxySL levels paralleled by clinical improvement,
including improved motor performance and increased un-
myelinated sciatic nerve ﬁbers.10 A pilot study of L-serine in 14
patients with HSAN1 similarly demonstrated reductions in
plasma 1-deoxySL levels.10 Here, we report a randomized,
placebo-controlled trial evaluating the safety and eﬃcacy of L-
serine as a treatment for HSAN1.
Methods
The primary research question of this study was whether
L-serine is safe and clinically eﬃcacious in humans with
HSAN1. The study provides Class I evidence that high-dose
oral L-serine supplementation is safe and signiﬁcantly slows
disease progression in HSAN1.
Standard protocol approvals, registrations,
and patient consents
Patients were enrolled at the Massachusetts General and
University of Massachusetts Hospitals (ClinicalTrials.gov
Identiﬁer: NCT01733407). The protocol was approved by
the institutional review boards at both sites and all participants
provided written informed consent. The US Food and Drug
Administration accepted the Investigational New Drug ap-
plication (110,957).
Patients
Eligibility required being at least 18 years of age and having
conﬁrmed HSAN1 based on SPTLC1 mutations and clinical
symptoms of a peripheral neuropathy. Exclusion criteria
comprised other risk factors for polyneuropathy, history of
nephrolithiasis, presence of other serious medical conditions,
need for anticoagulation, psychiatric disease or cognitive im-
pairment limiting ability to give consent, and exposure to
L-serine within 30 days prior to enrollment. Women who were
pregnant, breastfeeding, or planning to become pregnant
during the study were also excluded. Women of childbearing
age were advised to use contraception for the duration of the
study and were counseled to stop L-serine immediately and
notify the treating physician if they became pregnant.
Randomization and masking
After enrollment, patients were referred to the Massachusetts
General Hospital (MGH) pharmacy, where the research
pharmacist independently provided study medications based
on the allocation sequence. Patients were randomly assigned
to receive either L-serine (administered in powder form to be
dissolved in water) or matching placebo (dextrose hydrous
powder) in a 1:1 ratio. L-Serine and placebo powder were
identical in appearance, taste, and smell, and were centrally
packed and labeled before being distributed from MGH. The
randomization schedule used a permuted-block structure with
blocks of 4. The schedule and allocation sequence was gen-
erated using mrandomization.com by CLIPA Clinical Pack-
aging, an independent contract research organization. Only
the study biostatistician and MGH research pharmacist were
unblinded to the individual drug assignments in this study.
The principal investigator and project management, data
management, and site staﬀ were blinded to treatment group
assignments. Levels of alanine, citrulline, glycine, and serine
were scrubbed by the study biostatistician from amino acid
Glossary
1-deoxySL = 1-deoxysphingolipid; AFT = autonomic function testing; CI = conﬁdence interval; CIPN = chemotherapy-
induced peripheral neuropathy; CMT = Charcot-Marie-Tooth; CMT1A = Charcot-Marie-Tooth type 1A;CMTES = Charcot-
Marie-Tooth Examination Score; CMTNS = Charcot-Marie-Tooth Neuropathy Score; HSAN1 = hereditary sensory
autonomic neuropathy type I;MGH =Massachusetts General Hospital;NPS = Neuropathy Pain Scale; SF-36 = 36-item Short
Form health questionnaire; SPT = serine palmitoyltransferase.
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panel results prior to distribution to the study team to
maintain the blind. Unblinded laboratory assays and results of
sphingolipid analyses were not shared with the study team
until after the database was locked.
Procedures
L-Serine 400 mg/kg/d was administered in 3 divided doses.
This dose was chosen based on the HSAN1 pilot study and on
previous observations that higher doses can cause reversible
side eﬀects including nausea, vomiting, nystagmus, and
myoclonus.10,11 The active drug was manufactured at Ajino-
moto North America pharmacy and placebo was manufac-
tured at University of Iowa. Participants were instructed to
return all empty and unused study medication containers at
each visit. Drug compliance was assessed by tracking the
number of unused study medication bottles and analyzing
plasma L-serine and 1-deoxySL levels.
After providing informed consent, patients underwent phys-
ical examinations and laboratory testing to determine eligi-
bility. Eligible patients returned for baseline assessments and
were randomly assigned to treatment groups. Participants
were treated with either L-serine or placebo for 1 year, fol-
lowed by crossover to open-label L-serine by all participants
for 1 additional year. Follow-up visits were conducted at
24, 48, 72, and 96 weeks from baseline. Physical examina-
tion, Charcot-Marie-Tooth Neuropathy Score version 2
(CMTNS), laboratory studies including sphingolipid and
amino acid levels, and skin biopsy were performed at every
visit and adverse events were reviewed and coded toMedDRA
terms (version 16.1). Nerve conduction studies, autonomic
function tests, the 36-item Short Form health questionnaire
(SF-36), and the Neuropathy Pain Scale (NPS) were per-
formed yearly. Safety assessments comprised physical exam-
ination, adverse events, serious adverse events, and safety
laboratory tests. All clinical assessments were performed by
one of 2 examiners who were blinded to treatment group
assignments.
The primary endpoint was the CMTNS, a reliable and valid
composite score based on patient symptoms, signs, and
electrophysiology that has been validated to measure pro-
gression in CMT type 1A (CMT1A). The score covers 9
items, each scored on a 0–4 scale for a total of 0–36 points,
with higher scores indicating increased severity of neuropathy.
Scores are classiﬁed as reﬂecting mild (CMTNS ≤10), mod-
erate (CMTNS 11–20), or severe (CMTNS >20) neuropa-
thy. Secondary endpoints included nerve conduction studies,
autonomic function testing (AFT), density of epidermal
nerve ﬁbers at the distal leg and proximal thigh, the SF-36, the
NPS, patients’ dietary journals with focus on amino acid
consumption, plasma sphingolipid levels, plasma amino acid
levels, and adverse events.
Nerve conduction studies (peroneal–extensor digitorum
brevis, peroneal–tibialis anterior, tibial–abductor hallucis,
median–abductor pollicis brevis, and ulnar–abductor digiti
minimi motor responses, and sural, superﬁcial peroneal, ra-
dial, median, and lateral antebrachial sensory responses) were
performed by one of 2 electrophysiologists at MGH using the
same equipment and techniques. Limb temperature was
maintained greater than 32°C.
Comprehensive AFT evaluated cholinergic, adrenergic, and
sudomotor domains. Heart rate and blood pressure were
monitored during tilt-table testing, deep breathing, and Val-
salva maneuver. Deep breathing was performed at the rate of
6 breaths/minute for 1 minute. The Valsalva maneuver was
performed with an expiratory pressure of 40 mm Hg for 15
seconds. Participants were tilted for 10 minutes. Quantitative
sudomotor axonal reﬂex testing was performed at a simulation
current of 2 mA for 5 minutes. Blood pressure was monitored
continuously (Finometer; Finapres, Amsterdam, the Neth-
erlands; and Dinamap ProCare 10; GE, Fairﬁeld, CT). The
validated Composite Autonomic Scoring Scale was used to
quantitate and assess AFT results.12
For neuropathologic assessments, 3-mm-diameter skin
punches were removed from the standard distal leg site
(10 cm above the lateral malleolus) and in the upper thigh by
experienced neurologists using local anesthesia and standard
practices.13 Biopsies were ﬁxed in Zamboni ﬁxative, then
processed and analyzed by the clinical diagnostic skin biopsy
laboratory at MGH according to consensus standards. Free-
ﬂoating 50-mm vertical sections were labeled immunohis-
tochemically against PGP9.5, a pan-neuronal marker
(Chemicon, Temecula, CA), to reveal epidermal nerve ﬁbers
that were counted using standard rules by a skilled morpho-
metrist blinded to group allocation.
For sphingolipid analyses, discarded venous blood was sam-
pled in EDTA tubes and immediately frozen at 4°C until all
clinical laboratory testing was complete. Plasma was obtained
after spinning the samples at 3,400 rpm for 15 minutes at
room temperature. Samples were aliquoted, anonymized, and
immediately frozen to −80°C. For sphingoid base analysis, the
samples were shipped on dry ice to the University of Zurich.
The sphingoid base proﬁle was analyzed by liquid
chromatography/mass spectrometry after hydrolyzing the
N-acyl and O-linked headgroups as described earlier.14 Ana-
lyzed sphingoid bases included C16SO, C16SA, C17SO,
C17SA, C18SO, C18SA, C19SO, C19SA, C20SO, C20SA,
C18-SAdiene, 1-deoxysphinganine, and 1-deoxysphingosine.
Other serum measures included amino acids, complete blood
count, hepatic function, and renal function.
Statistical analysis
The proportion of participants advancing by more than 1
point in the CMTNS from baseline to the 48-week visit was
compared between the placebo and L-serine arms by Fisher
exact test. As a more sensitive assessment, longitudinal
changes in CMTNS were analyzed in a shared-baseline,
random-slopes linear mixed model with ﬁxed eﬀects of visit
(categorical) and treatment × postbaseline visit interaction
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and random participant-speciﬁc intercepts and slopes with
unstructured covariance. Subgroup analyses of sex, age,
baseline CMTNS, and time since symptom onset (median
split for all continuous measures) were examined by adding
ﬁxed eﬀects of subgroup, subgroup × visit, and subgroup ×
treatment × postbaseline visit. Forty-eight-week CMTNS
change scores were also compared by exact Wilcoxon rank
sum test. Changes in L-serine, log-transformed 1-deoxySL
levels, NPS scores, and SF-36 domain scores were all analyzed
in equivalent shared-baseline, random-slope linear mixed
models. Because of their coarse and strongly skewed distri-
bution, AFT and density change scores were analyzed by exact
Wilcoxon rank-sum test. Spearman correlation coeﬃcients
were used to estimate associations between CMTNS and
1-deoxySL levels at baseline and as change scores. All analyses
were performed in SAS (version 9.4; SAS Institute, Cary,
NC). Two-tailed p values are reported without adjustment for
multiple comparisons given the limited power of the trial.
Role of funding source and trial oversight
The study funders had no role in the study design, data col-
lection, data analysis, data interpretation, or writing of the
manuscript. The corresponding author and all coauthors had
full access to all the data in the study and had ﬁnal re-
sponsibility for the decision to submit for publication. The
protocol was approved by the institutional review board at
every site, and all participants provided written informed
consent. The trial was performed under a Food and Drug
Administration Investigational New Drug approval (110957)
and registered on ClinicalTrials.gov (NCT01896102). An
independent Data and Safety Monitoring Board reviewed the
safety data annually. The study was conducted in accordance
with the provisions of the Declaration of Helsinki and the
authors vouch for the conduct of the trial, adherence to the
trial protocol, and the accuracy of the data and analysis.
Data availability
Trial design, eligibility criteria, and primary and secondary
outcome measures have been published on clinicaltrials.gov.
Any data not published within this article are available in the
public repository of clinicaltrials.gov. Following publication,
anonymized data will be shared by request from any qualiﬁed
investigator.
Results
Eighteen participants were deemed eligible and enrolled into
the study between August 2013 and April 2014. There were
no screen failures. Nine were randomized to L-serine and 9 to
placebo (ﬁgure 1). Baseline characteristics were well-balanced
between the 2 study groups, except for higher epidermal nerve
ﬁber densities at the thigh biopsy site in the L-serine group
(table 1). Participants’ mean age (±SD) was 47.8 ± 14.0 years
(range 29.1–80.4 years), and 67% were female. Mean disease
duration since symptom onset was 24.7 ± 14 years (range
4–57 years). The average CMTNS at baseline was 22.6 ± 8.6
(range 5–33). All participants reported reduced sensation or
painful paresthesias in their feet as the presenting symptom
and all had experienced limb ulcers. One hundred percent of
participants in the L-serine group and 78% in the placebo
group completed the study. Of the 2 participants lost to
follow-up, one had a malignancy prior to initiating the study
and died of esophageal cancer before completing the study,
and another left the study in the second year due to disease
progression and increased work demands.
The primary outcome, deﬁned as a >1 point increase in
CMTNS over 1 year, consistent with progression of neuropa-
thy, was achieved by 1 participant in the L-serine group (11%)
and 2 participants in the placebo group (22%, p = 1.0). Par-
ticipants randomized to L-serine had steady reductions in
CMTNS over the 2 years of treatment (mean ± SE change of
−1.14 points ± 0.76 between baseline and 2 years, p = 0.15)
(ﬁgure 2). In contrast, participants taking placebo experienced
a mean ± SE increase of 1.1 point ± 0.47 in CMTNS during the
ﬁrst year of the study (p = 0.02). At 1 year, L-serine participants
experienced a decline in CMTNS relative to those taking pla-
cebo (−1.5 units, 95% conﬁdence interval [CI] −2.8 to−0.1, p=
0.03). Both groups improved on L-serine treatment during the
second year, with the relative diﬀerence in the CMTNS un-
changed (−1.4 units, 95% CI −3.6 to 0.76, p = 0.19). Com-
bining data from the ﬁrst year of L-serine treatment for all
participants (0–48 weeks for the L-serine group and 48–96
weeks for the placebo group) suggested a consistent treatment
eﬀect (−0.6 points on the CMTNS, p = 0.08, 95% CI −1.3 to
0.08), with no diﬀerence depending on the timing of treatment
initiation (p = 0.52). In addition to the CMTNS, we also
examined the Charcot-Marie-Tooth Examination Score
(CMTES), a subscore of the CMTNS, calculated as the sum of
the symptoms and signs with exclusion of the electrophysio-
logic measures. The CMTES showed similar results to
CMTNS (relative change of −1.2 points, 95% CI −2.4 to 0.0,
p = 0.05 at 1 year, and 0.83 points, 95% CI −2.7 to 1.0, p = 0.37
at 2 years), suggesting that electrophysiologic ﬁndings did not
contribute importantly to treatment response.
The CMTNS items that contributed most to the beneﬁt from
L-serine supplementation vs placebo included sensory symp-
toms, strength of legs on examination, and strength of arms on
examination (relative change of −0.48, 95% CI 0.92 to −0.04,
p = 0.03; −0.44, 95% CI −0.78 to −0.11, p = 0.01; and −0.40,
95% CI −0.77 to −0.03, p = 0.03, respectively). The distri-
bution of change scores in participants taking L-serine varied
across the component items. We performed subgroup anal-
yses evaluating the eﬀect of age (greater or less than 46 years),
sex, time from diagnosis (greater or less than 20 years), and
baseline CMTNS (greater or less than a score of 26 points) on
treatment response and found no signiﬁcant interaction be-
tween the listed variables and treatment eﬀect.
1-deoxySL levels declined signiﬁcantly in participants taking
L-serine vs those on placebo following 1 year of treatment
(41% decrease in 1-deoxysphingosine vs 9.2% increase on
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placebo, p = 0.001; 60% decrease in 1-deoxysphinganine vs
9% increase on placebo, p < 0.001) (ﬁgure 3). Most of the
decline in 1-deoxySL levels occurred during the ﬁrst 24 weeks
of treatment. Placebo participants experienced similar
declines in 1-deoxySL levels after crossing over to L-serine
treatment (39% decrease in 1-deoxysphingosine, p = 0.001;
and 66% decrease in 1-deoxysphinganine, p = 0.001). While
a positive correlation was observed between baseline
1-deoxySL levels and baseline CMTNS (r = 0.50, CI −0.01 to
0.81, p = 0.05), we observed limited evidence of association
between the change in 1-deoxySL levels and change in
CMTNS that was largely attributable to a favorable response
in one participant (r = 0.24, −0.33 to 0.69, p = 0.39) (ﬁgure 3).
No signiﬁcant change was seen in the canonical sphingolipid
levels following 1 year of treatment (6% decrease in sphin-
gosine, p = 0.16, and 15% decrease in sphinganine, p = 0.08).
At baseline, most of the distal leg skin biopsies were devoid of
epidermal nerve ﬁbers, whereas densities from the thigh site
varied widely (ﬁgure 4). At 1 year, only distal biopsies from
L-serine-treated participants showed evidence of reinnerva-
tion (median change = 8 vs 0 ﬁbers/mm2 skin surface area, p =
0.014). This pattern was not present at the thigh site, where
there were no signiﬁcant diﬀerences between the groups
(median change = 2 vs 26 ﬁbers/mm2, p = 0.099) (ﬁgure 4).
Changes in epidermal nerve ﬁber density at the distal site over
1 year were negatively correlated with changes in scores on
question 1 on the CMTNS, which measured patient-reported
sensory symptoms (r = −0.719, −0.888 to −0.380, p < 0.001);
however, the opposite relationship was found at the upper
thigh site (r = 0.62, 0.22–0.84, p = 0.004). A negative corre-
lation was also seen between changes in distal leg innervation
at 1 year and 1-deoxySL levels (for 1-deoxysphingosine r =
−0.73, −0.91 to −0.33, p = 0.001) (ﬁgure 4).
No treatment eﬀects were detected in nerve conduction
studies or AFT (table 2). In addition, none of the patient-
reported outcomes revealed signiﬁcant diﬀerences between
treatment groups (table 2). No signiﬁcant eﬀect of treatment
on NPS scores was observed, but mean levels of “unpleasant
Figure 1 Trial profile
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pain” were numerically lower among participants on L-serine
vs those on placebo at 1 year, with further relative reduction in
pain at 2 years (relative change of −0.18 ± 1.2 points, p = 0.88;
and −0.85 ± 1.4 points, p = 0.56, respectively). No diﬀerence
in “sharp pain” was seen between the 2 groups following
1 year of treatment (L-serine participants had relative change
of 0.14 ± 1.4 points, p = 0.92). No signiﬁcant eﬀect of treat-
ment on SF-36 scores was observed, but mean physical
functioning component scores were numerically lower in the
treatment group in the ﬁrst year and in both groups following
crossover to open-label L-serine (+4.2 points at 1 year in
L-serine group, 95% CI −4.2 to 1.5, p = 0.29) (table 2).
Table 1 Demographics and clinical characteristics at baseline
Variable Overall, mean ± SD
Treatment assignment, mean ± SD
L-Serine Placebo p Value
Age, y 47.8 ± 14.0 45.8 ± 11.0 49.9 ± 16.9 0.55
Age at onset, y 22.7 ± 7.5 23.8 ± 9.6 21.7 ± 5.1 0.57
Right ulnar motor amplitude–wrist, mV 3.29 ± 3.92 4.16 ± 4.59 2.42 ± 3.16 0.36
Right ulnar CV forearm, m/s 45.0 ± 14.7 45.7 ± 14.8 43.9 ± 16.6 0.86
Radial sensory nerve action potential, μV 7.32 ± 14.1 8.98 ± 17.2 5.46 ± 10.4 0.62
CMTNS 22.6 ± 8.6 20.6 ± 10.0 24.6 ± 7.0 0.34
CMTES 17.2 ± 5.8 15.8 ± 6.8 18.6 ± 4.5 0.33
ENFD distal leg, mm2 0.61 ± 2.15 0·00 ± 0·00 1.22 ± 2.99 0.24
ENFD upper thigh, mm2 35.8 ± 54.4 64.3 ± 66.4 7.3 ± 7.8 0.021a
Pain score (how sharp 0–9) 7.19 ± 2.88 7.25 ± 3.20 7.13 ± 2.75 0.93
Plasma serine level, μmol/L 117 ± 22 120 ± 30 114 ± 9 0.60
1-Deoxysphingosine, μmol/L 0.58 ± 0.23 0.49 ± 0.12 0·64 ± 0·27 0.22
1-Deoxysphinganine, μmol/L 0.28 ± 0.13 0.23 ± 0.08 0·31 ± 0·16 0.27
Total CASS score 2.89 ± 1.37 2.33 ± 1.22 3.44 ± 1.33 0.084
Abbreviations: CASS = Composite Autonomic Scoring Scale; CMTES = Charcot-Marie-Tooth Examination Score; CMTNS = Charcot-Marie-Tooth Neuropathy
Score version 2; CV = conduction velocity; ENFD = epidermal nerve fiber density.
a There was no significant difference between groups except for a higher baseline ENFD at the thigh in participants randomized to L-serine.
Figure 2 Change in primary endpoints
Charcot-Marie-Tooth Neuropathy
Score (CMTNS) and Charcot-Marie-
Tooth Examination Score (CMTES) in
patients taking L-serine vs placebo
during the trial period. Baseline val-
ues were normalized to zero, and
data represent the mean change
from baseline. At week 48, patients
on placebo crossed over to L-serine
(red arrows). I bars indicate 95%
confidence bounds.
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Figure 3 Change in plasma sphingolipid levels
Change in plasma levels of canonical sphingolipids (A, B) and neurotoxic 1-deoxysphingolipids (C, D) over the course of the study. Baseline values were
normalized to zero. Data represent the mean change from baseline. The correlation between the Charcot-Marie-Tooth Neuropathy Score (CMTNS) and
deoxysphingosine levels is plotted for baseline (E) and change at 48-week follow-up (F). I bars indicate 95% confidence bounds.
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Eighty-nine percent of the L-serine group and 100% of the
placebo group reported adverse eﬀects during the ﬁrst year
(table 3). Neither group had any serious adverse events, and
most adverse events were of mild to moderate severity.
During the second year, one placebo arm participant with
a preexisting malignancy died of esophageal cancer, which was
judged to be unrelated to L-serine. Fifty-six percent of par-
ticipants in the treatment group reported adverse events vs
89% among participants following cross-over to open-label
L-serine. Two participants (both of whom had crossed over
from placebo) temporarily suspended treatment in year 2 in
the setting of infection (bladder infection and a gastrointesti-
nal virus). Adverse events that were more common in par-
ticipants taking L-serine vs placebo included localized
infection (6 of 9 participants [67%] vs 4 of 9 participants
[44%]), MRSA infection (1 of 9 participants [11%] vs 0 par-
ticipants), osteomyelitis requiring amputation (2 of 9 partic-
ipants [22%] vs 0 participants), abdominal pain, and
dyspepsia (2 of 9 participants [22%] vs 0 participants). No
participants reported vomiting, nystagmus, acoustic startles,
or myoclonus, as in prior L-serine studies.11 Analysis of vital
signs, physical examination ﬁndings, and clinical laboratory
measurements did not reveal adverse eﬀects of L-serine.
Plasma L-serine levels were highly variable in both the treat-
ment and placebo group throughout the ﬁrst year of treat-
ment, with a nonsigniﬁcant relative increase seen among
participants randomized to L-serine (95.6 ± 48.3 μmol/L, p =
0.06), despite 1-deoxySL changes demonstrating good com-
pliance in the treatment group.
Discussion
In this randomized, double-blinded, placebo-controlled,
2-year trial in adults with HSAN1, L-serine treatment was
well-tolerated and produced biochemical improvement with
signiﬁcant reductions in 1-deoxySL levels. While the primary
Figure 4 Change in epidermal nerve fiber density (ENFD)
Skin biopsies from the standard distal leg site (lower calf)
were largely devoid of epidermal nerve fibers and dem-
onstrated an increase in ENFDat 1 year (p = 0.014) (A). Skin
biopsies from the upper thigh revealed no significant
change in ENFD in participants taking placebo vs serine
(B). Correlation between changes in ENFD in the lower calf
and changes in plasma deoxysphingosine levels is shown
in (C).
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outcome of proportion of patients progressing more than 1
point on the CMTNS at 1 year did not diﬀer between the
L-serine and placebo groups (11% vs 22%, p = 1.0), the dis-
criminatory power of this endpoint was limited by the small
sample size and low event rate in both arms. Participants
taking L-serine did demonstrate a signiﬁcant quantitative
improvement in CMTNS as compared to those taking pla-
cebo during the ﬁrst year of the study. Furthermore, placebo-
treated participants showed similar rates of improvement in
CMTNS after crossover to L-serine treatment, further sug-
gesting that L-serine may oﬀer clinical beneﬁt in HSAN1.
We found no evidence that the eﬀect of L-serine on CMTNS
diﬀered according to age, sex, disease duration, or baseline
CMTNS. The individual CMTNS items that contributed
most to the L-serine-associated beneﬁt vs placebo were
patient-reported sensory symptoms and upper and lower
extremity strength on examination; however, areas of im-
provement varied among participants. While no signiﬁcant
treatment eﬀect was seen on quality of life measures, the
observed numeric improvements seen on all the physical well-
being domains of the SF-36 were consistent with beneﬁt from
L-serine treatment. Although we previously reported that
some patients with HSAN1 experience worsening par-
esthesias on L-serine, potentially as a consequence of sensory
nerve regeneration, we did not observe any treatment-
associated worsening in sharp pain in this study.10 Treated
participants did not have fewer skin ulcers, one of the more
debilitating manifestations of HSAN1, and both skin infec-
tions and osteomyelitis occurred with higher frequency in the
treatment group. To our knowledge, there are no prior
reports of either alteration in immune function or heightened
propensity towards infection resulting from L-serine supple-
mentation. Many participants in our study had severe and
longstanding neuropathy and were therefore susceptible to
recurrent limb ulceration.1,15 Treatment earlier in the disease
course may therefore elucidate whether L-serine can prevent
or reduce infections in HSAN1.
L-Serine supplementation was associated with signiﬁcant
reductions in levels of 1-deoxySL, with near-normal levels
achieved within 24 weeks after starting on treatment, and
continued 1-deoxySL suppression throughout the 2-year
study period. In contrast to prior ﬁndings, supplementation
was not associated with changes in the canonical, serine-based
sphingolipids.10 There are conﬂicting data regarding the role
of endogenous lipid derangements in HSAN1, with initial
reports indicating abnormal levels of select species, and sub-
sequent studies showing no change in canonical lipid
proﬁles.3,5,16,17 Our ﬁndings further support the hypothesis
that the potential treatment eﬀect of L-serine is a consequence
of 1-deoxySL suppression rather than shifts in endogenous
Table 2 Change in secondary endpoints from baseline to 1 year
L-serine, mean ± SD
or mean (95% CI)
Placebo, mean ± SD
or mean (95% CI) p Valuea
Nerve conduction studies
Ulnar motor amplitude–wrist, mV 1.26 ± 1.42 −0.07 ± 1.12 0.026
Ulnar CV forearm, m/s 0.55 ± 4.58 −3.08 ± 4.72 0.26
Radial sensory amplitude, μV 0.74 ± 2.47 −1.69 ± 4.68 0.42
Autonomic function testing
Cardiovagal 0.11 ± 0.33 0.00 ± 0.50 1.0
Sudomotor −0.33 ± 1.12 −0.11 ± 0.60 0.84
Adrenergic 0.11 ± 0.60 0.22 ± 0.44 1.0
Total CASS score12 −0.11 ± 1.54 0.11 ± 0.93 0.97
Neuropathy pain scale
Unpleasant pain −0.02 (−2.39 to 2.35) 0.16 (−2.19 to 2.51) 0.88
Sharp pain 0.37 (−2.29 to 3.03) 0.23 (−2.41 to 2.88) 0.92
SF-36
Physical functioning component score 1.21 (−5.14 to 7.56) −2.97 (−9.33 to 3.40) 0.29
Social functioning component score 0.89 (−4.87 to 6.66) 1.25 (−4.54 to 7.03) 0.91
Abbreviations: CASS = Composite Autonomic Scoring Scale; CI = confidence interval; CV = conduction velocity; SF-36 = 36-item Short Form health
questionnaire.
a p Values from exact Wilcoxon rank-sum tests for nerve conduction studies and autonomic function testing. p Values from shared-baseline random-slope
models for Neuropathy Pain Scale and SF-36.
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sphingoid base formation.18 Post hoc analysis indicated
a positive correlation between baseline 1-deoxySL levels and
CMTNS; however, we did not observe a clear relationship
between the change in 1-deoxySL and neuropathy severity.
Regarding the 3 biomarkers evaluated (nerve conduction
studies, autonomic function, and epidermal innervation),
standard electrophysiologic measures did not prove helpful in
deﬁning treatment response in HSAN1. This is consistent
with prior studies in CMT.19 Only minimal autonomic ab-
normalities were seen at baseline, making treatment eﬀect
diﬃcult to detect. In contrast, interpretation of nerve con-
duction studies was limited by the paucity of recordable
sensory and motor responses prior to the start of treatment.
We had previously found density of epidermal innervation
promising in pilot studies, and studies in other small ﬁber
predominant neuropathies have demonstrated excellent
test–retest reliability.15,20 However, in the current study we
found high variability, particularly at the proximal site.20 The
main ﬁnding of a minor increase in the epidermal nerve ﬁber
density at the distal site in L-serine-treated participants (me-
dian change of 8 vs 0 ﬁbers/mm2, range 0–75, p = 0.014) is
surprising given the absence of treatment eﬀects at the
proximal site. In length-dependent neuropathies, re-
innervation would be expected to occur proximally, rather
than in the more severely aﬀected distal calf. The limitations
of all the major electrophysiologic and pathologic measures
underscore the importance of developing and evaluating
novel biomarkers for HSAN1, as well as other severe, small
ﬁber predominant polyneuropathies.
Our study had limitations, the most important being its small
sample size, which limited its statistical power. HSAN1 is very
rare, with an estimated prevalence of only a few hundred
patients worldwide, and large clinical trials in the disease are
therefore not feasible. Another limitation was the paucity of
validated outcome measures and longitudinal natural history
data speciﬁc to HSAN1. The CMTNS has been extensively
studied in CMT1A but not been validated in HSAN1. Both
neuropathies cause progressive, distally pronounced sensory
loss and muscle weakness; however, HSAN1 is also distinct in
its preferential involvement of the small nerve ﬁbers with
a propensity towards skin ulceration and neuropathic pain,
features that cannot be adequately assessed using the
CMTNS. Importantly, prior studies of CMT1A have shown
a CMTNS change of only 0.23–0.68 points a year, and
Table 3 Adverse events, irrespective of cause, in the randomized study
MedDRA system organ class/
preferred term
Placebo
period 1
(n = 9)
Placebo crossover to
L-serine (n = 9)
L-Serine
period 1
(n = 9)
Combined first-year exposure
to L-serine (n = 18)
Second-year exposure
to L-serine (n = 9)
L-Serine exposure, y 0 0–1 0–1 0–1 1–2
Any adverse event, n (%) 9 (100) 8 (89) 8 (89) 16 (89) 5 (56)
Vertigo 0 11 0 6 0
Gastrointestinal symptoms 11 0 22 11 0
Local swelling 0 11 0 6 0
Any infections or infestations 67 56 56 56 56
Any injury, poisoning, or
procedural complication
22 0 44 22 0
Electrolyte or CBCabnormality 11 11 0 6 11
Vitamin D deficiency 0 0 11 6 0
Musculoskeletal or connective
tissue disorder
33 0 22 11 0
Esophageal carcinoma 0 11 0 6 0
Oropharyngeal pain 0 11 0 6 0
Skin or subcutaneous tissue
abnormality
11 11 22 17 11
Finger amputation 0 0 11 6 11
Hypertension 11 0 0 0 0
Abbreviation: CBC = complete blood count.
Values are percentages.
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a recent natural history study of HSAN1 demonstrated no
change in CMTNS over 1 year.21,22 In the current study, we
did observe an increase in CMTNS scores in the placebo
group (1.1 points ± 0.53, p = 0.04); however, this must be
interpreted with caution given the small sample size.23
Importantly, many participants in our study had advanced
neuropathy at enrollment (mean CMTNS 22.6 ± 8.6), and it
is possible that earlier treatment would be more eﬀective.
Given that nerve injury in HSAN1 may begin in infancy or
even in utero, long before symptoms are noted, treatment
may be most beneﬁcial in childhood with study endpoints
focusing on delaying symptom onset and slowing disease
progression. Furthermore, the optimal treatment dose of
L-serine may require further examination. We selected a dose
of 400 mg/kg/d on the basis of prior reports of reversible side
eﬀects at higher doses; however, these studies were performed
in young children with disorders of serine metabolism rather
than in adults with normal serine synthesis but dysfunctional
use.11 The absence of signiﬁcant adverse events in our study
suggests that even higher doses could be considered, although
it is not clear if this would add beneﬁt since 1-deoxySL for-
mation was adequately suppressed in our study. In addition,
we found that plasma L-serine levels do not reliably reﬂect
treatment status. It is likely that these levels do not correlate
with L-serine uptake into neurons, as plasma amino acid levels
are heavily inﬂuenced by their metabolism in both liver and
muscle. A follow-up study evaluating the clinical eﬀect of
L-serine in a larger number of patients using more sensitive
biomarkers such as neuromuscular MRI is needed to help
conﬁrm the clinical eﬃcacy of L-serine in HSAN1 and deﬁne
the optimal timing and dosing of treatment.24
Our ﬁnding that L-serine reduces levels of 1-deoxySL in
humans, and thereby may improve neuropathy, may have
implications beyond HSAN1. Elevated plasma 1-deoxySL
levels have been observed in patients with metabolic syndrome
and type 2 diabetes mellitus and have been implicated as
possible contributors to diabetic sensory neuropathy.7,8,25–27
Elevated 1-deoxySL levels have also been observed in paclitaxel-
induced peripheral neuropathy (chemotherapy-induced pe-
ripheral neuropathy [CIPN]).28,29 L-serine supplementation
has been shown to lower 1-deoxySLs and improve sensory
function in a rat model of diabetic neuropathy as well as
paclitaxel-induced CIPN.25,30 1-DeoxySLs may therefore also
be important biomarkers and therapeutic targets in other small-
ﬁber-predominant neuropathies.
We have shown that supplementation with high doses of
L-serine is well-tolerated in patients with HSAN1 and results
in reduced levels of neurotoxic 1-deoxySL. Our ﬁndings also
suggest that treatment may slow clinical progression of the
disease although further research will be needed to conﬁrm this
and optimize timing and dosage of L-serine supplementation.
L-Serine may be the ﬁrst rational therapy for HSAN1 as it
addresses the metabolic eﬀect of the underlying gene defect.
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